Takara Bio starts phase I for therapy of pancreatic cancer using oncolytic virus (HF 10) in combination with chemotherapy

The test (TBI-1401) on patients with uncurable and unresectable pancreatic cancer is targeted to evaluate dose-limiting toxicity. HF 10 is administered intratumorally by ultrasonic endoscope., and gemcitabine and nab paclitaxel are administered in combination.

Takara Bio news release, June 1, 2017

Most popular posts: